2.62
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BRAIN Biotech
Its shares trade on XETRA under the ticker BNN.DE. It has been listed since 9 February 2016. In the fiscal year to 30 September 2025, it reported revenue of €49.6m and a net loss of €11.7m. At that date it held total assets of €66.3m and shareholders' equity of €1.8m.
B.R.A.I.N.Biotechnology Research & Information Network AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen. The company went IPO on 2016-02-09. The firm develops drugs, bioactive natural compounds and enzymes for customers in the chemical and pharmaceutical industries, as well as in the food and cosmetics industries. The company offers research and development collaboration, as well as strategic partnerships and exclusive licensing agreements through all phases of enzyme and biological compound discovery to application development and production. The firm's product portfolio includes EvoSolution, METAGENOME, BRAINzyme, LIL, ABEL, CompActives and BioCompActives.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 9 Feb 2016
- Employees
- 283
- Website
- brain-biotech.de ↗
Leadership
Pay as last reported
- Dr. Michael MajerusIndependent Chairman of the Supervisory Board, since 2019€51,000
- Mr. Adriaan MoelkerChairman of the Management Board, Chief Executive Officer€620,000
- Dr. Anna EichhornIndependent Deputy Chairman of the Supervisory Board, since 2017€53,000
- Mr. Michael SchneiderChief Financial Officer, Member of the Management Board
- Mr. Stephen CatlingIndependent Member of the Supervisory Board€31,000
- Dr. Florian SchnabelMember of the Supervisory Board
- Ms. Christine UekertMember of the Supervisory Board
- Ms. Martina SchusterInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BRAIN Biotechnology Research and Information Network AG has established itself as a leader in biotechnology research and development. The company possesses a highly skilled team of researchers and scientists who are dedicated to innovation and problem-solving in the biotech industry.
- BRAIN AG offers a wide range of biotechnological products across various industries, including food and beverages, healthcare, and agriculture. This diversity in its product portfolio enables the company to cater to different market demands and mitigate risks associated with depending on a single product.
- The company has strategic partnerships with leading organizations in the biotechnology and pharmaceutical sectors. These partnerships provide access to additional resources, expertise, and market opportunities, enhancing BRAIN AG's competitive advantage and market positioning.
Weaknesses
- BRAIN AG heavily relies on collaborations with external partners for the commercialization and distribution of its products. This dependence on external factors may introduce uncertainties and challenges in terms of maintaining control over the supply chain, pricing, and market presence.
- The success of BRAIN AG is closely tied to market conditions and customer demand for biotechnological solutions. Economic downturns or shifts in consumer preferences could impact the company's revenue and profitability, making it vulnerable to market fluctuations.
Opportunities
- The biotechnology industry continues to witness significant growth due to advancements in technology, increasing need for sustainable solutions, and rising healthcare demands. BRAIN AG can capitalize on this opportunity by further developing its products and expanding its market presence.
- The company can explore untapped markets within the biotechnology sector, such as pharmaceuticals, renewable energy, and environmental solutions. By diversifying its offerings and targeting new customer segments, BRAIN AG can broaden its market reach and drive long-term growth.
Threats
- BRAIN AG operates in a highly competitive industry, facing competition from both established players and emerging startups. To maintain its market position, the company must continually innovate, differentiate its offerings, and adapt to changing customer needs to stay ahead of the competition.
- The biotechnology sector is subject to stringent regulations and compliance requirements, which may pose challenges for BRAIN AG in terms of product development, safety testing, and commercialization. Adhering to these regulations and staying up-to-date with changing policies is crucial to avoid potential legal and reputational risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.